Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.

Bossart, Simon; Daneluzzi, Cloé; Cazzaniga, Simone; Ramelet, Albert-Adrien; Uthoff, Heiko; Seyed Jafari, S Morteza; Baumgartner, Marc; Hunger, Robert E; Heidemeyer, Kristine; Willenberg, Torsten (2023). Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review. Journal of the European Academy of Dermatology and Venereology : JEADV, 37(2), pp. 274-283. Wiley 10.1111/jdv.18639

Preview

Text Acad_Dermatol_Venereol_-_2022_-_Bossart_-_Skin_hyperpigmentation_after_sclerotherapy_with_polidocanol_A_systematic_review.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview

Skin hyperpigmentation after sclerotherapy with polidocanol-containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol-containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches, and truncal varices with polidocanol-containing sclerosants was performed. Reported incidence rates, follow-up periods, and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for polidocanol 0.5% (liquid and foam), and between 13% and 73% for polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for polidocanol 1% (liquid and foam), from 16% to 17% for polidocanol 2% (foam), and from 7.4% to 32.5% for polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam polidocanol 1% to 3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol-related sclerotherapy are poor and should be improved by higher-quality research.

Interest & Impact

Downloads

163 since deposited on 06 Oct 2022
155 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item